PLA2G4A and melanoma: Inhibition of group IVA phospholipase A2 reprogrammed effector T-cell lipid metabolism, prevented T-cell senescence in vitro, and enhanced antitumor immunity and immunotherapy efficacy in melanoma mouse models.